UK’s Morphogen-IX secures $23.2 mln to advance preclinical development

12/20/2018 7:10:00 AM (GMT)

UK drug discovery company Morphogen-IX has secured $23.2 million in Series B financing.

Morphogen-IX will use the funds to support formal preclinical development of its lead candidate, MGX292, and commencement of clinical trials by 2021.

Medicxi led the financing round alongside investments from Cambridge Innovation Capital and Cambridge Enterprise.

The company has bagged a total of $25.1 million in over 2 funding rounds.

Morphogen-IX Ltd.

All success stories are prepared by Investsize editors which is selecting elite and remarkable information from press releases and anonymous news sources.There is no charge applied for any success stories which is published . Those published success stories are not investment advices and doesnt offer recommendations Alternate Text